Clinical trialNCT05756569RecruitingPhase 2Interventional

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

SponsorEmory UniversityEnrollment25Bladder AdenocarcinomaBladder Squamous Cell CarcinomaLocally Advanced Bladder CarcinomaMalignant Renal Pelvis NeoplasmMalignant Ureter NeoplasmMalignant Urethral Neoplasm+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jacqueline Brown, MD
Emory University Hospital/Winship Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
Jacqueline Brown, MD
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, United States
Jacqueline Brown, MD
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Jacqueline Brown, MD
Recruiting
Grady Health System
Atlanta, Georgia, United States
Jacqueline Brown, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Sept 2023
Primary completion: 16 Dec 2026
Completion: 16 Dec 2027
Last update posted: 28 Jul 2025
Registered enrollment: 25
Registry id: NCT05756569

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.